- Top 10 Pipelines 11,766 views
- Annual Report: Top 10 Pipelines 10,300 views
- Celgene Snaps Up Merck & Co.’s Giant Complex in New Jersey 9,500 views
- Top 100 Biotechnology Companies Special Report: The Acquisition Game 3,700 views
The Pulse of the Pharmaceutical Industry
BOSTON, July 9, 2015— PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced expanded services and capabilities in model-based drug development (MBDD) through their Quantitative Clinical Development (QCD) group. The PAREXEL QCD team also offers leadership in all strategic and quantitative aspects of clinical pharmacology for biopharmaceutical companies to help expedite drug development, minimize risk, and support regulatory approval processes.
Leveraging mathematical models for a quantitative analysis of the relationship between drugs, disease and patients, modeling and simulation can predict a drug’s benefits and adverse effects in a patient population prior to conducting a clinical trial. MBDD can improve the efficiency of clinical development by providing quantitative justification for trial design, dose selection, and decisions during trial execution. In addition, quantitative clinical pharmacology throughout the lifecycle of a drug candidate supports high quality regulatory packages to help secure regulatory approval.
“The biopharmaceutical landscape continues to show dramatic change, putting companies under increasing pressure to deliver on their pipeline, to identify more effective means of picking the ‘winners’ and efficiently developing these medicines under financial constraints. In addition, regulatory authorities around the world have increasingly accepted model-based techniques as a standard component of new drug applications,” said Frank Hoke, PhD, Vice President of QCD, PAREXEL. “Our goal is to reduce risk along the drug development continuum – for drug developers and for patients – while helping companies make sound investment decisions and accelerating their drug’s journey to market.”
PAREXEL’s Quantitative Clinical Development, one of the largest groups in the industry providing modeling and simulation, is led by Dr. Hoke and supported by a dedicated team of more than 30 scientists with an aggregate of 400+ years of combined clinical development experience. Dr. Hoke and a number of colleagues joined PAREXEL from GlaxoSmithKline’s Clinical Pharmacology Modeling and Simulation department.
For more information about PAREXEL’s QCD modeling and simulation and quantitative clinical pharmacology services, visit PAREXEL.com/solutions/clinical-research/quantitative-clinical-development.
Source: BioSpace Featured News
Sorry. No data so far.